Eridani S, Burdick L, Maggio L, Cunietti E, Periti M, Arosio A, Perrone G
Int J Clin Pharmacol Biopharm. 1978 Oct;16(10):482-5.
A selected case file of 32 patients with carcinoma of the lung which had passed the stage of surgical cure was randomized in 3 arms and treated with different schedules: regimen A, adriamycin plus cyclophosphamide; regimen B, the BACON combination, slightly modified; regimen CVP, cyclophosphamide plus vincristine plus prednisone. Response rate and survival curves were analyzed. Statistical evaluation showed a significant increase in survival of B versus A, but not versus CVP, while other factors such as the initial performance status and the response rate seemed to have a marked influence on survival time. No significant correlation was observed with different histiotypes within each regimen. All three regimens compare favorably with patients who received only supportive treatment.
选取32例已过手术治愈阶段的肺癌患者的病例档案，随机分为三组，采用不同治疗方案：A方案，阿霉素加环磷酰胺；B方案，对BACON联合方案稍作修改；CVP方案，环磷酰胺加长春新碱加泼尼松。分析缓解率和生存曲线。统计评估显示，B方案与A方案相比，生存期显著延长，但与CVP方案相比无显著差异，而其他因素如初始体能状态和缓解率似乎对生存时间有显著影响。各治疗方案内不同组织学类型之间未观察到显著相关性。与仅接受支持治疗的患者相比，所有三种治疗方案均具有优势。
